Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/05/24
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell TherapiesGlobeNewsWire • 10/24/24
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/04/24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024GlobeNewsWire • 08/07/24
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion TechnologyGlobeNewsWire • 06/26/24
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/03/24
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024GlobeNewsWire • 05/06/24
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should KnowZacks Investment Research • 03/07/24
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingGlobeNewsWire • 03/05/24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023GlobeNewsWire • 02/28/24
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaGlobeNewsWire • 11/09/23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023GlobeNewsWire • 11/07/23
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 09/27/23
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformPRNewsWire • 09/11/23